What is the recommended Paxlovid (nirmatrelvir/ritonavir) dose for a non‑hospitalized adult with mild‑to‑moderate COVID‑19 who tests positive for SARS‑CoV‑2 and is at risk for severe disease, including adjustments for renal impairment?

Paxlovid Dosing for SARS-CoV-2 Positive Patients

The standard dose of Paxlovid is nirmatrelvir 300 mg (two 150 mg tablets) plus ritonavir 100 mg (one 100 mg tablet), all three tablets taken together twice daily for 5 days, initiated within 5 days of symptom onset 1.

Standard Dosing

For adults with normal to mild renal impairment (eGFR ≥60 mL/min):

• Nirmatrelvir 300 mg + ritonavir 100 mg twice daily for 5 days
• Take with or without food
• Must start within 5 days of symptom onset 1

This regimen is supported by 2024 American College of Physicians guidelines, which recommend nirmatrelvir-ritonavir combination therapy for symptomatic patients with confirmed mild-to-moderate COVID-19 who are at high risk for progression to severe disease 2. The evidence shows reductions in all-cause mortality, COVID-19 mortality, hospital admissions, and serious adverse events 2.

Renal Dose Adjustments

Moderate Renal Impairment (eGFR 30-59 mL/min)

Reduce to nirmatrelvir 150 mg (one 150 mg tablet) + ritonavir 100 mg (one 100 mg tablet) twice daily for 5 days 1.

This dose reduction is critical because renal impairment increases nirmatrelvir exposure, which may increase the risk of adverse reactions 1.

Severe Renal Impairment (eGFR <30 mL/min)

The FDA label states Paxlovid is not recommended in severe renal impairment or end-stage renal disease on dialysis 1. However, emerging research from 2024-2026 challenges this restriction:

• A phase 1 study (EPIC-SRI) demonstrated that nirmatrelvir 300/100 mg on Day 1, followed by 150/100 mg once daily on Days 2-5 was well-tolerated in patients with severe renal impairment, including those on hemodialysis, with no treatment-related adverse events 3
• Multiple case series in kidney transplant recipients with severe renal dysfunction showed safety and efficacy with modified dosing 4, 5

Clinical approach for severe renal impairment: Given the high mortality risk in this population and emerging safety data, consider using the modified regimen (300/100 mg loading dose, then 150/100 mg once daily) with close monitoring, particularly in high-risk patients where benefits likely outweigh risks. This represents an off-label use requiring careful risk-benefit assessment 3, 4.

Key Clinical Considerations

Timing is Critical

• Initiate as soon as possible after COVID-19 diagnosis
• Must start within 5 days of symptom onset for effectiveness 1

Hepatic Impairment

• No dose adjustment needed for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment
• Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of safety data 1

Common Pitfalls to Avoid

1. Drug interactions: Ritonavir is a potent CYP3A inhibitor. Review all medications before prescribing—some require dose adjustment, interruption, or are contraindicated 1

2. Renal function assessment: Always calculate eGFR before prescribing. Prescriptions should specify the numeric dose of each component to ensure proper renal dosing 1

3. Contraceptive counseling: Ritonavir reduces efficacy of combined hormonal contraceptives; advise alternative or additional barrier contraception 1

4. HIV resistance risk: In patients with uncontrolled or undiagnosed HIV-1 infection, Paxlovid may lead to HIV protease inhibitor resistance 1

Treatment Duration

Always complete the full 5-day course regardless of symptom improvement. The treatment course should not be extended beyond 5 days 1.